A5073500738- Analytical Chemistry and Chromatography
- Protein purification and stability
- Microfluidic and Capillary Electrophoresis Applications
- Monoclonal and Polyclonal Antibodies Research
- Chromatography in Natural Products
- Mass Spectrometry Techniques and Applications
- Viral Infectious Diseases and Gene Expression in Insects
- Analytical Methods in Pharmaceuticals
- HER2/EGFR in Cancer Research
- Biosimilars and Bioanalytical Methods
- Medical History and Research
- Pesticide Residue Analysis and Safety
- Glycosylation and Glycoproteins Research
- Metabolomics and Mass Spectrometry Studies
- Analytical chemistry methods development
- Historical Medical Research and Treatments
- Pharmacological Effects and Assays
- Molecular Biology Techniques and Applications
- Toxin Mechanisms and Immunotoxins
- Psychopathy, Forensic Psychiatry, Sexual Offending
- Psychoanalysis and Social Critique
- RNA and protein synthesis mechanisms
- Animal testing and alternatives
- Virus-based gene therapy research
- History and advancements in chemistry
Waters (United States)
2021-2023
University of Lausanne
2012-2021
University of Geneva
2012-2021
HES-SO University of Applied Sciences and Arts Western Switzerland
2020
University of Veterinary Medicine Vienna
2019
Charles Humbert 8
2016
Budapest University of Technology and Economics
2011-2013
Gedeon Richter (Hungary)
2008-2010
Hungarian Academy of Sciences
1990-1995
HUN-REN Institute for Nuclear Research
1995
The 21st century has been particularly productive for the biopharmaceutical industry, with introduction of several classes innovative therapeutics, such as monoclonal antibodies and related compounds, gene therapy products, RNA-based modalities. All these new molecules are susceptible to aggregation fragmentation, which necessitates a size variant analysis their comprehensive characterization. Size exclusion chromatography (SEC) is one reference techniques that can be applied. analytical...
Therapeutic drugs and multivalent vaccines based on the delivery of mRNA via lipid nanoparticle (LNP) technologies are expected to dominate biopharmaceutical industry landscape in coming years. Many these innovative therapies include several nucleic acid components (e.g., nuclease guide RNA) posing unique analytical challenges when monitoring quantity quality each individual payload substance formulated LNP. Current methods were optimized for single analysis often lack resolving power needed...
In this proof-of-concept study, rituximab, which is a reference therapeutic monoclonal antibody (mAb), was characterized through the implementation of online, selective comprehensive two-dimensional liquid chromatography (sLC×LC) coupled with mass spectrometry (MS), using middle-up approach. setup, cation exchange (CEX) and reverse-phase (RPLC) were used as first second separation dimensions, respectively. As illustrated in work, combination these two chromatographic modes allows direct...
In recent years, the biopharmaceutical industry's interest in gene therapy modalities has increased dramatically. To warrant their quality during manufacturing and upstream/downstream process, fit-for-purpose analytical methods play a crucial role overall control strategy. However, characterization of products remains challenging due to large size, structural complexity, heterogeneity, potential instability, limited sample availability. addressing some these challenges with innovative...
Health authorities have highlighted the need to determine oligonucleotide aggregates. However, existing technologies limitations that prevented reliable analysis of size variants for large nucleic acids and lipid nanoparticles (LNPs). In this work, acid LNP aggregation was examined using prototype, low adsorption ultrawide pore exclusion chromatography (SEC) columns. A preliminary study conducted column's physicochemical properties. difference in aggregate content (17.8 vs 59.7 %) found a...
Biopharmaceutical products, in particular messenger ribonucleic acid (mRNA), have the potential to dramatically improve quality of life for patients suffering from respiratory and infectious diseases, rare genetic disorders, cancer. However, safety such products are particularly critical require close scrutiny. Key product-related impurities, as fragments aggregates, among others, can significantly reduce efficacy mRNA therapies. In present work, possibilities offered by size exclusion...